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1. Introduction
Natural killer (NK) cells represent about 5–15% of circulating lymphocytes [1] and belong to the 
innate immune system, in particular due to their invariant antigen receptors. Morphologically, 
as opposed to “small lymphocytes,” most of them are typically large azurophilic granules 
containing lymphocytes (LGL) [2], characterized by high cytoplasmic:nuclear ratio. They have 
initially been referred to as k or null lymphocytes (non-B and non-T cells), with the highest 
cytotoxic capacity [3, 4], because they lack conventional T-cell membrane markers and the 
surface membrane immunoglobulin (smIg) [5, 6]. NK cells mediate resistance against intra-
cellular pathogens, mainly viral-infected, bacteria-infected and protozoa-infected cells, and 
have the potential to restrain cancer and metastasis. They are also able to contribute to the 
activation and the regulation of the immune responses, as well as the orientation of adap-
tive immune responses [7, 8]. More recently, NK cells were recognized as a subtype of type 1 
innate lymphoid cells (ILC1), which express the transcription factor T-box expressed in T cells 
(T-bet), and defined by the production of the T helper cell type 1 (Th1)-associated cytokine 
interferon gamma (IFN-γ) and the inability to produce Th2 cell-associated and Th17 cell-asso-
ciated cytokines [9]. As a result of collective work, this book has therefore the ultimate purpose 
to address the most fundamental aspects of NK cells, as well as their clinical applications for 
cancer immunotherapy.
2. Lineage of NK cells
NK cells constitute a third lymphoid line derived from a common T-cell and B-cell bone marrow 
precursor. Unlike T cells, NK cells do not have a specialized differentiating organ, are matured 
inside of bone marrow, and can develop even in athymic mice. The acquisition of their functions 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
does not use recombination-activating gene (RAG) enzymes for rearrangement of their receptor 
genes or complete V(D)J recombination as is the case for T cells or B cells [10] and is considered 
as the only lymphocytes without a clonally specific receptor [11]. Additionally, in contrast to 
the conventional αβ T cells, the genesis of NK cells appears to be independent of the self-major 
histocompatibility complex (MHC), although they have different recognition specificities of 
allogeneic MHC molecules.
Mature NK cells are able to self-renew and possibly persist in the host for months or years. 
Nevertheless, unlike long-lived CD8+ and CD4+ T cells that retain a “memory-like” phenotype 
and function after homeostatic proliferation, expanded NK cells return to a quiescent phenotype 
and respond with comparable kinetics against viral challenge [10].
3. Localization of NK cells
NK cells are present in the bloodstream and in the lymphatic vessels [12], as well as in pla-
centa, spleen, liver, lungs, tonsils, peripheral ganglia, and bone marrow where they act as 
sentinels. Nevertheless, it appears that they have no access to other tissues apart from inflam-
matory responses. Of note, it has been reported that the homeostasis-driven NK cells can 
reside in both lymphoid and nonlymphoid organs for a long time [13].
4. LGL surface markers
4.1. CD3− LGL markers
In human, the LGL population can be separated into CD3+ and CD3− subtypes. The majority of 
LGL TCR−CD3− expresses CD16 (or FcγRIIIA, low-affinity receptor for the Fc portion of immu-
noglobulin G, 90%), CD56 (neural cell adhesion molecule [N-CAM], > 95%), and some markers 
of T cells, such as CD7 (100%), CD11b (80–80%), CD2 (70–80%), CD4 (<5%), and CD8 (15–20%).
4.2. CD19−CD3− NK cell subsets
NK cells are CD3−CD19− LGLs [14]. They thus lack two main markers of T cells (CD3+) and 
B cells (CD19+). In human peripheral blood, five NK cell subpopulations can be separated 
depending on the relative presence and expression levels of CD16 and CD56 markers [15]:
1. CD56bright CD16− (50–70% of CD56bright)
2. CD56bright CD16dim (30–50% of CD56bright)
3. CD56dim CD16− (small proportion)
4. CD56dim CD16bright (at least 90% of all peripheral blood NK cells)
5. CD56− CD16bright (small proportion)
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The NK cells can also be separated into two subgroups according to the expression levels of 
the CD16 and CD56 markers in healthy individuals (Table 1).
5. Immune roles of NK cells
After maturation, NK cells migrate to the blood to provide innate defense against tumor cells 
and metastases, as well as infected cells by intracellular pathogens (such as viruses, bacteria, 
and protozoan parasites). Additionally, NK cells are also involved in the acute rejection of 
bone marrow transplants [16]. Finally, in addition to their ability to secrete various cytokines 
and regulate the immune response, activated NK cells are also involved in tissue remodel-
ing through their ability to secrete matrix metalloproteinases (MMPs), in both physiological 
and pathological abnormalities, within the tumor microenvironment, through the cleavage of 
CD16 from the cell surface [17].
6. MHC I as molecular basis of target recognition by NK cells
The activation of NK cells does not require prior sensitization with an antigen. However, their 
activities are inversely correlated with the density of MHC class I molecules (MHC I), which 
are expressed on the surface of certain nucleated cell lines, with the exception of red blood 
cells and certain tissues such as salivary glands, brain, cornea, anterior chamber of the eye, 
liver, testis, fetotrophoblast, hair matrix, and proximal nail matrix [18].
NK cell subgroup
CD16brightCD56dim/+ NK cells CD16dim/−CD56bright NK cells
Proportion ≥90% of PBNKCs ≤10% of PBNKCs
Cytotoxic/lytic granules +++ +
ADCC function +++ +
LAK cell activity +++ +++
Natural cytotoxicity +++ +
Cytokine production + +++
Immunoregulation + +++
NK cell migration Migration to the sites of acute inflammation  
(arrive very early to the sites of inflammation)
Migration to the SLOs
ADCC, antibody-dependent cell-mediated cytotoxicity; LAK, lymphokine-activated killer; NK, natural killer; PBNKCs, 
peripheral blood natural killer cells; SLO, secondary lymphoid organs.
Table 1. Key features of CD16brightCD56dim/+ and CD16dim/−CD56bright NK cells.
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7. “Missing self” hypothesis
NK cells lack antigen-specific receptors, but their activation can be blocked by an inhibitory 
signal generated by their recognition of MHC I alleles on host cells. However, the absence 
of MHC molecules I triggers an activating signal [19]. Nevertheless, the recognition of MHC 
I molecules would be one of the major causes of the tumor escape from NK cell immune 
surveillance and activation. Therefore, among the current therapeutic strategies is the use of 
monoclonal antibodies that target the NK cell inhibitory receptors.
8. NK cell-activating and inhibitory receptors
NK cells express two major types of receptors, inhibitory and activating receptors, that may 
belong to one of the following receptor categories:
(i) Immunoglobulin superfamily (IgSF) - activating or inhibitory - receptors.
(ii) C-type lectin family - activating or inhibitory - receptors.
(iii) Natural cytotoxicity - activating - receptors (NCRs).
NK cell receptors can be either MHC class I-dependent or MHC class I-independent receptors 
(Table 2).
8.1. MHC class I-dependent receptors
8.1.1. Killer cell immunoglobulin-like receptors
Killer cell immunoglobulin-like receptors (KIRs) are a family of type I transmembrane glyco-
proteins belonging to the immunoglobulin superfamily (IgSF) receptors and grouped together 
with other receptors of the same IgSF. KIR genes are found in a cluster on human chromosome 
19q13.4 within the 1 Mb leukocyte receptor complex (LRC) [28].
KIR molecules are also expressed by some T-cell subtypes. The ligands for several KIRs are sub-
sets of MHC I molecules.
8.1.1.1. Dominant receptors on NK cells
NK cell functions are regulated by a balance between activating and inhibitory signals [29]. Their 
receptors recognizing the same MHC I or other ligands are polymorphic and highly homologous 
and can induce two opposite signals, but one of them dominates signal transduction. Usually, the 
presence of MHC I molecules on a cell generates a dominant negative signal, but some ligands 
induced by abnormal or virus-encoded cell damage can stimulate activating receptors and gen-
erate a dominant positive signal. Additionally, the absence of MHC I molecules is not sufficient 
to induce a dominant activating signal, especially in normal cells. From the molecular point of 
view, it is the length of the cytoplasmic domain that determines the function of NK cells. Thus, 
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long-tailed receptors (L) are associated with an inhibitory function upon ligand binding via an 
immune tyrosine-based inhibitory motif (ITIM), while short ones (S) lack the ITIM and instead 
associate with the TYRO protein tyrosine kinase-binding protein to transduce activating signals. 
In the rare situation where an NK cell co-expresses an inhibitory and an activating KIR (KAR) 
with the same specificity, the inhibitory receptors block activation signals at an early step [30].
NK cell receptors Ligands
Inhibitory NK cell 
receptors
MHC class 
I-dependent 
receptors
IgSF 
receptors
KIR2DL (1) KIR2DL1/NKAT1 
(CD158a)
(2) KIR2DL2/NKAT6 
(CD158b1)
(3) KIR2DL3/NKAT2 
(CD158b2)
(4) KIR2DL5 (CD158f)
HLA-Cw2, 
HLA-Cw4, 
HLA-Cw5, 
HLA-Cw6
HLA-Cw1, 
HLA-Cw3, 
HLA-Cw7, 
HLA-Cw8
HLA-Cw1, 
HLA-Cw3, 
HLA-Cw7, 
HLA-Cw8
Unknown
KIR3DL (1) KIR3DL1/NKAT3 
(CD158e1)
(2) KIR3DL2 (CD158k)
(3) KIR3DL3 (CD158z)
HLA-Bw4
HLA-A3/
HLA-A11
Unknown
ILT (1) IL-T2 (CD85j)
(2) IL-T5 (CD85a)
(3) IL-T8 (CD85c)
HLA-A, HLA-B, 
HLA-C, CMV 
UL-18
Unknown
Ligand still needs 
to be identified
CTLRs CD94-
NKG2A/B
CD159a HLA-E loaded 
with HLA-A, 
HLA-B, HLA-C, 
or HLA-G leader 
peptide
MHC class 
I-independent 
receptors
CTLRs KLRG1 E-cadherin
NKR-P1A CD161 LLT1
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NK cell receptors Ligands
Activating NK cell 
receptors/KARs
MHC class 
I-dependent 
receptors
IgSF 
receptors
KIR2DL KIR2DL4/KIR103 
(CD158d)*
HLA-G, 
HLA-Bw4
KIR2DS (1) KIR2DS1 (CD158h)
(2) KIR2DS2 (CD158j)
(3) KIR2DS3/NKAT7
(4) KIR2DS4 (CD158i)
(5) KIR2DS5 (CD158g)
HLA-Cw2, 
HLA-Cw4, 
HLA-Cw5, 
HLA-Cw6
HLA-Cw1, 
HLA-Cw3, 
HLA-Cw7, 
HLA-Cw8
With no detectable 
avidity for C1, C2, 
or any other HLA 
class I epitope
HLA-C (weak)
With no detectable 
avidity for C1, C2, 
or any other HLA 
class I epitope
KIR3DS KIR3DS1/NKB1 (CD158e2) Ligand still needs 
to be identified 
(HLA-Bw4-I80, 
HLA-Bw4-T80, 
allotype 
HLA-B*2705?)
CTLRs CD94-
NKG2C
CD159c HLA-E loaded 
with HLA-A, 
HLA-B, HLA-C, 
or HLA-G leader 
peptide
CD94-
NKG2E/H
CD159a HLA-E loaded 
with HLA-A, 
HLA-B, HLA-C, 
or HLA-G leader 
peptide
NKG2D CD314 MICA, MICB, 
ULBP1, ULBP2, 
ULBP3, ULBP4
MHC class 
I-independent 
receptors
IgSF 
receptors
NCR1 NKp46 (CD335) Viral HA and 
NDHN
NCR2 NKp44 (CD336) Viral HA
NCR3 NKp30 (CD337) BAT3, B7-H6 on 
human tumor cells
Adapted from Ref. [20] and completed from Refs. [21–26]. Costimulatory NK cell receptors are not presented here.*An 
unusual activating KIR with L cytoplasmic and hybrid D0-D2 structure domains, displaying very weak inhibitory 
potential [27]. BAT3, B-associated transcript 3; B7-H6, B7 homolog 6; HLA, human leukocyte antigen; HLA-Bw4-I80, HLA-
Bw4 molecules containing an isoleucine in position 80; ILTs, immunoglobulin-like transcripts; ILRs, immunoglobulin-
like receptors; HA, hemagglutinin; IgSF, immunoglobulin superfamily; KAR, killer cell-activating receptors; KIR, killer 
cell immunoglobulin-like receptor; LLT1, lectin like transcript-1; CTLR, C-type lectin-like receptor; MICA/MICB, major 
histocompatibility complex class I-related chain A/B; KLRG1, co-inhibitory receptor killer cell lectin like receptor G1; 
NCR, natural cytotoxicity receptor; NK cell, natural killer cell; NDHN, Newcastle disease hemagglutinin-neuraminidase; 
NKAT, natural killer-associated transcript; ULBP, UL-16-binding proteins.
Table 2. Inhibitory and activating human NK cell receptors.
Natural Killer Cells6
8.1.1.2. Classification of KIR molecules
KIR molecules are classified into two types according to the number of extracellular Ig-like 
domains (D), 2D and 3D, and by whether they have a long (L) or short (S) cytoplasmic domain 
(Figure 1) [31].
8.1.2. CD94-NKG2 C-type lectin receptor complex
C-type lectin receptors are characterized by calcium-dependent carbohydrate recognition 
domain (CRD) and the presence of one or more C-type lectin-like (CTLD) domains. They play 
a crucial role in enabling NK cells to discriminate between self and nonself [32, 33]. The CD94-
NKG2 C-type lectin receptors have been found to be expressed predominantly on the surface 
of a majority of NK cells and on subsets of CD8+ T cells [34] and to be involved in NK cell-
mediated recognition of MHC I molecules [35]. They are encoded by the NK gene complex 
(NKC) on human chromosome 12 (12p13.3–12p13.4). NKG2 receptors recognize the nonclas-
sical MHC class I HLA-E molecule and can provide either an activating signal through their 
noncovalently association with the immunoreceptor tyrosine-based activation motif (ITAM)-
containing DNAX adaptor protein of 12 kDa (DAP12) or an inhibitory signal when they contain 
an immunoreceptor tyrosine-based inhibitory motif (ITIM).
The cell surface molecule CD94 is a common invariant chain in five different disulfide-
linked hetero dimeric transmembrane glycoprotein complexes, including CD94-NKG2A, 
CD94-NKG2B, CD94-NKG2C, CD94-NKG2E, and CD94-NKG2H [36].
NKG2F is expressed in the cytosol and therefore does not form heterodimers with CD94. NKG2D 
(apparently not belonging to the NKG2 family) is expressed on the cell surface of NK cells, γδ 
T cells, and subsets of CD4+ and CD8+ T cells as a homodimer. It lacks an ITIM sequence and is 
Figure 1. Structure of inhibitory and activating KIRs. DAP12, DNAX adaptor protein of 12 kDa; FcεRI-γ, high-affinity 
immunoglobulin epsilon receptor subunit gamma; ITAM, immunoreceptor tyrosine-based activation motif; ITIM, 
immunoreceptor tyrosine-based inhibitory motif; KIR, killer cell immunoglobulin-like receptor. This Figure was 
illustrated using image fragments from Servier Medical Art.
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not associated with CD94. Its signaling is achieved by association with two dimers of DAP10, a 
transmembrane adaptor molecule containing a tyrosine-based signaling motif (YINM), carrying 
phosphatidylinositol-3 kinase-binding sites in their cytoplasmic tails and recruiting growth fac-
tor receptor-bound protein 2 (Grb2) [37].
Both NKG2A and NKG2B are alternative spliced products from a single gene. They can dimer-
ize with CD94 to form inhibitory receptors through their cytoplasmic domains, which contain 
two ITIMs. Conversely, CD94-NKG2C, CD94-NKG2E, and CD94-NKG2H dimers and homodi-
mer-forming NKG2D and the orphan receptor NKG2F activate NK cells [37–39].
8.2. MHC class I-independent receptors
There are at least three activating and two inhibitory MHC class I-independent receptors.
8.2.1. Natural cytotoxicity receptors
Natural cytotoxicity receptors (NCRs) are composed by a heterogeneous group of molecules 
belonging to IgSF and include NKp46 (NCR1), NKp44 (NCR2), and NKp30 (NCR3) activating 
receptors targeting most tumor cell lines. They are characterized by a type I transmembrane 
domain containing a positively charged amino acid residue and a short cytoplasmic tail. All 
these transmembrane type I receptors are expressed almost exclusively by NK cells. Binding 
of one or more of these receptors with a specific ligand leads to the increased NK cell activa-
tion and cytotoxicity [40]. It has been reported that these receptors can initiate tumor targeting 
by recognition of heparan sulfate on cancer cells [41].
8.2.2. C-type lectin receptors
C-type lectin receptors include mostly killer cell lectin-like receptor subfamily G member 1 
(KLRG1) and KLRB1 (also known as NK1.1, NKR-P1A, or CD161), which inhibit the cytotox-
icity of NK cells and therefore prevent tissue damage. NKR-P1A is encoded by the KLRB1 
gene and recognizes lectin like transcript-1 (LLT1) as a functional ligand. Its signaling in NK 
cells has previously been known to involve the activation of acid sphingomyelinase, which 
represent the catabolic pathway for N-acyl-sphingosine generation as a second messenger 
for the induction of apoptosis, proliferation, and differentiation [42]. KLRG1 is expressed by 
antigen-experienced (memory) CD4+ and CD8+ T cells and by a large proportion of NK cells 
and naive phenotype CD4+ and CD8+ T cells in umbilical cord blood, as well as in a substantial 
subset of γδ T cells [43]. KLRG1 can bind three of the classical cadherins (E, N, and R), which 
are ubiquitously expressed in vertebrates and mediate cell-cell adhesion by homotypic and 
heterotypic interactions [44]. It has also been postulated to be a marker of senescence [45].
9. NK cells in alarming situations
Situations related to cellular stress resulting from the presence of intracellular infectious agents 
and changes in self-elements (the presence of damaged-self [damage-associated molecular 
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patterns (DAMPs)] or altered-self [tumor-associated molecular patterns (TAMPs)]) induce 
an increase in the expression of ligands that can “exclusively” stimulate activating receptors 
(major histocompatibility complex class I-related chain A [MICA], MICB, UL-16-binding pro-
teins [ULBP]1, ULBP2, ULBP3, ULBP4, viral hemagglutinin, Newcastle disease hemaggluti-
nin-neuraminidase, B7-H6, etc.) and consequently activate NK cell cytotoxicity.
10. NK cell-based immunotherapy in cancer
The main current therapeutic strategies, especially in allogeneic hematopoietic cell trans-
plantation (HCT), are based on the use of NK cells through their education to render them 
alloreactive against tumor targets missing self-MHC ligand. In practice, autologous or haplo-
identical transplantation of NK cells requires obtaining of a very large number of pure and 
cytotoxic cells. Additionally, a favorable mismatch of the human leukocyte antigen class I 
(HLA I) molecules between donor and recipient tissues, or the absence of inhibitory KIR 
ligands in the recipient’s HLA repertoire (KIR mismatch in the receptor-ligand model) allows 
NK cells in the graft to reduce its rejection by the host and the attack of residual leukemia 
cells, as well as the best prediction of the risk of relapse (Figure 2) [46, 47]. Finally, other 
promising approaches aim to induce an increase in their cytotoxic activities in the treatment 
of both hematopoietic and solid cancers by blocking inhibitory receptor signal transduction.
11. Conclusions
The specific structural and functional features of NK cells describe them as major players in 
innate antitumor immunosurveillance and in the fight against infection. Their availability at 
the proximity of cellular stress signals allows them to effectively control both the process of 
carcinogenesis and the development of infectious diseases. Nevertheless, their activities seem 
Figure 2. Role of KIR ligand mismatch in killing leukemic targets. AR, activating receptor; AL, activating ligand; IR, 
inhibitory receptor; KIR, killer cell immunoglobulin-like receptor. (Adapted from Ref. [26]. Images of cells are provided 
from Servier Medical Art.).
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to be strongly immunomodulated by cell microenvironment factors. Therefore, one of the 
best therapeutic strategies should create an ideal microenvironment for NK cell infiltration 
within target tissues while decreasing functions of their inhibitory receptors and enhancing 
their cytotoxic activities. Such a strategy should contribute not only to substantially increase 
the efficacy of targeted immunotherapies but also to prevent relapse after transplantation.
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